Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc.
Kalbe/Hisamitsu Pharmaceuticals (Adventure Bay) Inc.
Native name
久光製薬株式会社
Hisamitsu Seiyaku kabushiki gaisha
Company typePublic KK
TYO: 4530
NAG: 4530
FSE: 4530
IndustryPharmaceuticals
Founded1847; 177 years ago (1847)
HeadquartersTosu, Saga 841-0017, Japan (Kyushu head office)
Marunouchi, Chiyoda, Tokyo100-6330, Japan (Tokyo head office)
Area served
Worldwide
Key people
Hirotaka Nakatomi
(President and CEO)
Products
  • Salonpas and other pain relief products
  • Robitussin, Caltrate, Advil (Japan-only)
  • Eye drops
  • Anti fungal, anti-inflammatory, dermatologic, central nerve system, respiratory system medicines
RevenueIncrease JPY 150.63 billion (US$1.47 billion) (FY 2013)[1]
Increase JPY 21.35 billion (US$209.5 million) (FY 2013)
Number of employees
2,949 (consolidated, as of 28 February 2014)
Websiteglobal.hisamitsu
Footnotes / references
[2]

The Hisamitsu Pharmaceutical Co., Inc. (久光製薬株式会社, Hisamitsu Seiyaku kabushiki gaisha), headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug (OTC) products, especially external pain relieving products such as the transdermal patch.[3] Hisamitsu has specialised in transdermal drug delivery system technology[4] (TDDS) since the introduction of its original line of patches in 1903.[5]

Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration (FDA).[6][7]

  1. ^ "Financial Highlights". Hisamitsu Pharmaceutical. Archived from the original on April 30, 2017. Retrieved April 6, 2015.
  2. ^ "Company Snapshot". Bloomberg Businessweek. Retrieved April 6, 2015.
  3. ^ "Company Profile". Nikkei Asian Review. Nikkei Inc. Archived from the original on December 26, 2017. Retrieved August 7, 2017.
  4. ^ Geeta Aggarwal Dr. Sanju Dhawan. "Transdermal Drug Delivery System, transdermal patches, transdermal dosage form". Pharmainfo.net. Archived from the original on June 26, 2010. Retrieved May 12, 2010.
  5. ^ "Hisamitsu History". Hisamitsu Pharmaceutical. Retrieved May 12, 2010.
  6. ^ Matsuyama, Kanoko (18 October 2009). "Hisamitsu Wins U.S. FDA Approval for Pain Relieving Skin Patch". Bloomberg L.P. Archived from the original on 2015-05-25.
  7. ^ "Press Release relating to FDA Approval for SALONPAS® PAIN RELEAF PATCH (code: FS-67, topical analgesic product) under NDA" (PDF) (Press release). Hisamitsu Pharmaceutical. February 22, 2008. Retrieved 2021-03-11.